Efficacy and safety of canagliflozin among patients with type 2 diabetes mellitus: A systematic review and meta-analysis

Efficacy and safety of canagliflozin among patients with type 2 diabetes mellitus: A systematic review and meta-analysis

Objective: To evaluate the efficacy and safety of canagliflozin in combination therapy among patients with type 2 diabetes mellitus with inadequate glycemic control. Methods: Two review authors independently searched for the relevant randomized controlled clinical trials from the Cochrane Central Re...

Full description

Bibliographic Details
Main Authors:	Kirandeep Kaur, Nishkarsh Likhar, Amit Dang, Gurpreet Kaur
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2015-01-01
Series:	Indian Journal of Endocrinology and Metabolism
Subjects:	Canagliflozin genital infections hemoglobin A1c type 2 diabetes mellitus
Online Access:	http://www.ijem.in/article.asp?issn=2230-8210;year=2015;volume=19;issue=6;spage=705;epage=721;aulast=Kaur

Similar Items

A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus
by: K M Prasanna Kumar, et al.
Published: (2017-01-01)

Canagliflozin review – safety and efficacy profile in patients with T2DM
by: Jakher H, et al.
Published: (2019-02-01)

Clinical Efficacy of Different Doses of Canagliflozin Combined with Metformin in the Treatment of Type 2 Diabetes Mellitus: a Meta-analysis
by: Yuying CHEN, Xiaodong LI, Yunzhao TANG, Daiqing LI
Published: (2022-05-01)

The Use of Canagliflozin in Diabetes Mellitus Type 2 on Renal Outcome: A Systematic Review
by: Vikri Haikal, et al.
Published: (2024-01-01)

Efficacy and safety of canagliflozin 300 mg in overweight and obese type 2 diabetes mellitus patients in a real-world setting: COLOR study
by: Pankaj Aneja, et al.
Published: (2019-01-01)

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis
by: Seko Y, et al.
Published: (2018-11-01)

Comparative evaluation of empagliflozin, canagliflozin and sitagliptin cardioprotective properties in rats with experimental type 2 diabetes mellitus
by: A. V. Simanenkova, et al.
Published: (2021-07-01)

Canagliflozin alters the gut, oral, and ocular surface microbiota of patients with type 2 diabetes mellitus
by: Limin Wang, et al.
Published: (2023-10-01)

Short-term outcomes of type 2 diabetes mellitus patients treated with canagliflozin in real-world setting
by: Manash P Baruah, et al.
Published: (2016-01-01)

Renal, cardiovascular and safety outcomes of canagliflozin in patients with type 2 diabetes and nephropathy in East and South‐East Asian countries: Results from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation Trial
by: Takashi Wada, et al.
Published: (2022-01-01)

Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus: A multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group, phase III study in Japan
by: Takashi Wada, et al.
Published: (2022-12-01)

Risk of Diabetic Ketoacidosis Associated with Sodium Glucose Cotransporter-2 Inhibitors: A Network Meta-Analysis and Meta-Regression
by: Kannan Sridharan, et al.
Published: (2024-03-01)

Real-World Clinical Outcomes Associated with Canagliflozin in Patients with Type 2 Diabetes Mellitus in Spain: The Real-Wecan Study
by: Juan J. Gorgojo-Martínez, et al.
Published: (2020-07-01)

The Efficacy of Canagliflozin on Type 2 Diabetic Nephropathy in Male Rats
by: Manal M.G. Mourad*, et al.
Published: (2023-07-01)

Therapeutic Effects of Canagliflozin and Zinc Sulphate Alone and in Combination on Pancreatic Histology in Type-2 Diabetic Rat Model
by: Bushra Suhail, et al.
Published: (2020-12-01)

Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China
by: Xingyun Hou, et al.
Published: (2019-05-01)

Efficacy and safety of twice-daily treatment with canagliflozin, a sodium glucose co-transporter 2 inhibitor, added on to metformin monotherapy in patients with type 2 diabetes mellitus
by: Rong Qiu, MD, PhD, et al.
Published: (2014-06-01)

Investigation of the Effect of Canagliflozin on the Disposition Index, a Marker of Pancreatic Beta Cell Function, in Patients with Type 2 Diabetes
by: Takahara M, et al.
Published: (2020-11-01)

Remission effect of Canagliflozin in patients with newly diagnosed type 2 diabetes mellitus: a protocol for a multicenter, parallel-group, randomized, controlled, open-label trial
by: Xue Yang, et al.
Published: (2023-10-01)

An evidence-based practice-oriented review focusing on canagliflozin in the management of type 2 diabetes
by: Messana JA, et al.
Published: (2017-02-01)

Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome
by: Davies MJ, et al.
Published: (2017-01-01)

Canagliflozin: from glycemic control to improvement of cardiovascular and renal prognosis in patients with type 2 diabetes mellitus. Resolution of Advisory Board
by: M. V. Shestakova, et al.
Published: (2022-01-01)

Simplification of complex insulin regimens using canagliflozin or liraglutide in patients with well‐controlled type 2 diabetes: A 24‐week randomized controlled trial
by: Yasuyo Ando, et al.
Published: (2021-10-01)

In vivo assessment of the pharmacokinetic interactions between donafenib and dapagliflozin, donafenib and canagliflozin in rats
by: Xueru He, et al.
Published: (2023-06-01)

Synthesis of New Derivatives of Berberine Canagliflozin and Study of Their Antibacterial Activity and Mechanism
by: Jinsheng Li, et al.
Published: (2024-01-01)

Synthesis of Berberine and Canagliflozin Chimera and Investigation into New Antibacterial Activity and Mechanisms
by: Wenhui Hao, et al.
Published: (2022-05-01)

Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial
by: Abhinav Sharma, et al.
Published: (2024-02-01)

Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial
by: Kenya Kusunose, et al.
Published: (2021-09-01)

The role of canagliflozin in the prevention of stroke and chronic kidney disease in patients with type 2 diabetes mellitus: an expert council resolution
by: M. V. Shestakova, et al.
Published: (2023-11-01)

Predictive Factors of Renal Function Decline in Patients with Type 2 Diabetes Treated with Canagliflozin in the Real-Wecan Study
by: Juan J. Gorgojo-Martinez, et al.
Published: (2022-09-01)

SGLT2 Inhibitor Canagliflozin Alleviates High Glucose-Induced Inflammatory Toxicity in BV-2 Microglia
by: Ching-Tien Lee, et al.
Published: (2023-12-01)

De-Intensification of Antidiabetic Treatment Using Canagliflozin in Patients with Heart Failure and Type 2 Diabetes: Cana-Switch-HF Study
by: Luis M. Pérez-Belmonte, et al.
Published: (2021-05-01)

Canagliflozin promotes osteoblastic MC3T3-E1 differentiation via AMPK/RUNX2 and improves bone microarchitecture in type 2 diabetic mice
by: Peiyang Song, et al.
Published: (2022-12-01)

Double‐blinded, randomized, and controlled study on the effects of canagliflozin after bariatric surgery: A pilot study
by: Sangeeta R. Kashyap, et al.
Published: (2020-06-01)

Use of the SGLT2 inhibitor canagliflozin for control of refractory equine hyperinsulinemia and laminitis
by: Eleanor M. Kellon, et al.
Published: (2022-08-01)

Role of Canagliflozin on function of CD34+ve endothelial progenitor cells (EPC) in patients with type 2 diabetes
by: Seshagiri Rao Nandula, et al.
Published: (2021-02-01)

A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor
by: Chang Hee Jung, et al.
Published: (2014-08-01)

Candidemia Following Ureteric Stent Placement in a Patient With Type 2 Diabetes Treated With Canagliflozin
by: Rishi Raj, et al.
Published: (2019-01-01)

Pharmacokinetic Interactions between Canagliflozin and Sorafenib or Lenvatinib in Rats
by: Yanjun Cui, et al.
Published: (2022-08-01)

Effectiveness and Tolerability of the Intensification of Canagliflozin Dose from 100 mg to 300 mg Daily in Patients with Type 2 Diabetes in Real Life: The INTENSIFY Study
by: Juan J. Gorgojo-Martinez, et al.
Published: (2023-06-01)